North America Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The North America human microbiome market size is expected to reach US$ 2,811.82 million by 2031 from US$ 654.89 million in 2023. The market is estimated to record a CAGR of 20.0% from 2023 to 2031.

Executive Summary and North America Human Microbiome Market Analysis:

North America is the largest market for epigenetics and microbiome research, with the US holding the largest market share, followed by Canada. The market growth in North America is characterized by robust research activities on the human microbiome, increased funding for biotechnology, a rise in health consciousness among the population, and an increase in the demand for probiotics and prebiotics to treat chronic diseases. Moreover, an increase in focus on the development of microbiome therapeutics, the rise in the number of conferences in this region, and the presence of local key players are likely to stimulate growth and contribute to exceptional revenue generation for the human microbiome market in North America.

North America Human Microbiome Market Strategic Insights

Get more information on this report Request Free Sample PDF

North America Human Microbiome Market Segmentation Analysis

Key segments that contributed to the derivation of the North America human microbiome market analysis are type, application, and disease type.

• Based on type, the North America human microbiome market is bifurcated into product and software and services. The product held a larger share of the market in 2023.The product segment is further sub segmented into probiotics and prebiotics.
• Based on application, the North America human microbiome market is segmented into therapeutics, diagnostics, and research. The therapeutics held the largest share of the market in 2023.
• Based on disease type, the North America human microbiome market is segmented into obesity, diabetes, autoimmune disorder, cancer, GIT, and others. The GIT held the largest share of the market in 2023.

North America Human Microbiome Market Outlook

Government initiatives and support programs significantly impact the human microbiome market growth. Governments frequently give large sums of money and grants for studies on the human microbiome. This financial assistance speeds up the development of novel treatments, devices, and diagnostics. Funding supports the innovation and commercialization of products by startups and small-to-medium-sized enterprises (SMEs) in the human microbiome sector. For instance, the project launched by NIH can transform understanding of human health and prevent, diagnose, and treat various conditions. Part of the NIH’s Roadmap for Medical Research, the Human Microbiome Project will award US$ 115 million to researchers over the next five years. Regulating frameworks tailored to human microbiome-based products may be established or improved by governments, which would shorten the time and expense involved in introducing novel treatments to the market. Well-defined regulations guarantee the safety and efficacy of products, thereby increasing consumer trust and market uptake.

North America Human Microbiome Market Country Insights

Based on country, the North America human microbiome market comprises the US, Canada, and Mexico. The US held the largest share in 2023.

The application of human microbiome is rapidly growing in the field of biotechnology; it is emerging as a significant therapy to treat various chronic diseases. Hence, research and development on human microbiome-based therapeutics has grown significantly in the US, leading to increased private investment and advances in environmental microbiome engineering. According to an article published in Nature in 2019, over the past decade, the US has made the largest investment of ~US$ 1 billion toward human microbiome research. Approximately 20% of this funding has been utilized for two phases of the Human Microbiome Project (HMP), which aims to create the necessary research resources for studying the human microbiome. HMP was launched in 2007 to establish a comprehensive toolbox consisting of reference data sets, computational techniques, analytical methods, and clinical protocols. This endeavor has proven to be successful, as roughly 75% of the NIH grant recipients for microbiome research from 2012 to 2016, working across more than 100 diseases, relied on HMP data and tools in their funding applications. Financed by the US National Institutes of Health (NIH), the HMP has significantly accelerated human microbiome research both within the US and on a global scale. The rise in research activities is likely to offer opportunities for the development of innovative therapies in the market.

Product launches by various market players and product approvals by regulatory authorities are increasing the demand for human microbiome therapeutics in the US. For instance, in November 2022, Ferring Pharmaceuticals obtained US Food and Drug Administration (FDA) approval for its REBYOTA (fecal microbiota, live-jslm). This is a novel first-in-class microbiota-based live biotherapeutic indicated to prevent the recurrence of Clostridioides difficile infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. difficile infection.

North America Human Microbiome Market Report Highlights

North America Human Microbiome Market Company Profiles

Some of the key players operating in the market MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Human Microbiome Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

North America Human Microbiome Market Country and Regional Insights